David Gerber, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Karyopharm
    Topic:
    Clinical trial
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BerGenBio
    Topic:
    Clinical trial
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca
    Topic:
    Clinical trial
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Sagimet
    Topic:
    Clinical trial
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Gilead
    Topic:
    Medicine
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Catalyst Therapeutics
    Topic:
    Consulting
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Topic:
    Advisory Board
    Date added:
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sanofi
    Topic:
    Advisory Board
    Date added:
    01/03/2022
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Regeneron
    Topic:
    Advisory Board
    Date added:
    01/03/2022
    Date updated:
    08/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Walgreens
    Topic:
    Pharmacy
    Date added:
    05/16/2023
    Date updated:
    08/22/2024

Pages

Return to 2024 Oncology Year in Review (RP2407A)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.